In addition to inhibiting constitutive NF-κB signaling, doxycycline inhibited signal-induced NF-κB activation in GCB-DLBCL cell lines (Figure 1G), which exhibit minimum constitutive NF-κB activity [11, 13]. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.